HRAS and hepatocellular carcinoma: In addition to inducing acute liver damage, DEN administration results in HCC associated with activating Hras mutations (Chen et al., 1993; Buchmann et al., 1991) and inactivating Trp53 mutations (Smith et al., 1991).